phrykt

XBiotech Inc. (XBIT): who owns it and who trades it

As of Nov 16, 2026, XBIT insiders reported 2 purchases worth $855K in the last 12 months. The largest buyer was John Simard (Director), with $855K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling XBiotech

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, XBIT insiders reported $855K of open-market purchases and $0 of sales.

Purchases, 12 months
$855K
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 13, 2026

Purchases and sales by month

$711K$711KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026John SimardDirectorPurchase70,000$2.05$143KForm 4
Oct 26, 2026John SimardDirectorPurchase368,524$1.93$711KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John SimardDirector, 10% owner$855K–Nov 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

XBIT short interest

Low short interest. 1.0% of XBIT shares are sold short: about 1 share in 97. Over the last 12 reports the number of shares short went up 71%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 315,307 XBIT shares were sold short, 1.0% of the shares outstanding, up 4.8% from the report before. At the average daily volume of 119,215 shares, buying them all back would take about 2.6 trading days (days to cover).

Shares short, % of all shares

1.03%May 15Oct 301.22%

Days to cover

2.6May 15Oct 3014.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026315,3071.03%+5%119,2152.6
Oct 15, 2026300,9080.99%-8%46,4466.5
Sep 30, 2026328,0661.08%-5%32,94710.0
Sep 15, 2026347,1191.14%+1%69,8895.0
Aug 31, 2026342,8321.12%+3%26,03813.2
Aug 14, 2026332,9751.09%+2%27,17912.2
Jul 31, 2026325,4031.07%+16%41,9647.8
Jul 15, 2026281,4700.92%+2%38,9557.2
Jun 30, 2026275,5700.90%+28%32,4848.5
Jun 15, 2026215,0740.71%+19%30,7817.0
May 29, 2026181,2750.59%-1%22,8008.0
May 15, 2026184,0070.60%+6%25,0567.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

XBiotech company events

XBiotech filed 2 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 26, 2026.

  1. Oct 26, 2026LeadershipXBiotech, Inc. announces that the Board of Directors has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard to serve as Co-Chief Executive Officers of the Company effective October 23, 2026. Filing
  2. Dec 9, 2025LeadershipXBiotech, Inc. announces that John Simard notified members of the Board of Directors beginning on December 5, 2025 of his intent to retire from his role as President and Chief Executive Officer of the Company, effective as of December 8, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

XBiotech financials

Famous investors that hold XBIT

2 of the 50 well-known investors we track reported holding XBIT in their latest 13F filing. The largest position is Jim Simons's, worth $148K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202667,355$148K0.0%+62%
Israel Englander · Millennium ManagementQ3 202658,647$128K0.0%-26%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about XBiotech Inc. (XBIT) stock

Are XBIT insiders buying or selling?

In the last 12 months, XBIT insiders reported 2 open-market purchases worth $855K and no sales. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in XBIT?

As of Oct 30, 2026, 315,307 XBIT shares were sold short, 1.0% of the shares outstanding, up 4.8% from the report before. At the average daily volume of 119,215 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.

Which famous investors hold XBIT?

2 of the 50 well-known investors we track reported XBIT in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $148K. See all holders.

Executive pay

XBiotech's chief executive was paid a total of $30.1M for the year ended Dec 31, 2025, up 382% from $6.2M the year before. In the last 12 months, XBiotech's executives and directors bought $855K of stock on the open market and sold none.

Chief executive, total pay$30.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$27.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$385KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.